Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 21
- Registration Number
- NCT06883552
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
Phase 2
Not yet recruiting
- Conditions
- Rectal Cancer
- Interventions
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-03-19
- Target Recruit Count
- 130
- Registration Number
- NCT06884670
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Locally Recurrent Colorectal Cancer
- Interventions
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06881537
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, China
Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC
Phase 1
Not yet recruiting
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- Drug: Furmonertinib Mesylate
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 288
- Registration Number
- NCT06868732
Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)
Phase 2
Recruiting
- Conditions
- Intrahepatic Cholangiocellular Carcinoma
- Interventions
- Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)Procedure: cryoablation
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 92
- Registration Number
- NCT06860477
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Phase 2
Not yet recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Target Recruit Count
- 140
- Registration Number
- NCT06856837
- Locations
- 🇦🇹
SCRI CCCIT Ges.m.b.H., Salzburg, Austria
🇦🇹Ordensklinikum Linz GmbH, Linz, Austria
🇦🇹Noe LGA Gesundheit Thermenregion GmbH, Wiener Neustadt, Austria
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
Phase 1
Recruiting
- Conditions
- Colorectal CancerLiver MetastasisLDRT
- Interventions
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Target Recruit Count
- 9
- Registration Number
- NCT06848465
- Locations
- 🇨🇳
Army Medical Center, Chongqing, Chongqing, China
🇨🇳Daping Hospital, Army Medical University, Chongqing, Chongqing, China
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
Phase 2
Recruiting
- Conditions
- MCRC
- Interventions
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT06829355
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China
Neoadjuvant Low-Dose Radiotherapy Plus Targeted-Immunotherapy vs Targeted-Immunotherapy Monotherapy in Resectable HNSCC: A Randomized Trial
Phase 2
Recruiting
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 98
- Registration Number
- NCT06804850
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 3
Not yet recruiting
- Conditions
- Gastric Cancer
- Interventions
- Drug: Levo-Leucovorin
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 269
- Registration Number
- NCT06793917
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath